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Summary
Background The ARTemis trial was developed to assess the eﬃ  cacy and safety of adding bevacizumab to standard 
neoadjuvant chemotherapy in HER2-negative early breast cancer.
Methods In this randomised, open-label, phase 3 trial, we enrolled women (≥18 years) with newly diagnosed HER2-
negative early invasive breast cancer (radiological tumour size >20 mm, with or without axillary involvement), at 
66 centres in the UK. Patients were randomly assigned via a central computerised minimisation procedure to three 
cycles of docetaxel (100 mg/m² once every 21 days) followed by three cycles of ﬂ uorouracil (500 mg/m²), epirubicin 
(100 mg/m²), and cyclophosphamide (500 mg/m²) once every 21 days (D-FEC), without or with four cycles of 
bevacizumab (15 mg/kg) (Bev+D-FEC). The primary endpoint was pathological complete response, deﬁ ned as the 
absence of invasive disease in the breast and axillary lymph nodes, analysed by intention to treat. The trial has 
completed and follow-up is ongoing. This trial is registered with EudraCT (2008-002322-11), ISRCTN (68502941), and 
ClinicalTrials.gov (NCT01093235).
Findings Between May 7, 2009, and Jan 9, 2013, we randomly allocated 800 participants to D-FEC (n=401) and Bev+D-
FEC (n=399). 781 patients were available for the primary endpoint analysis. Signiﬁ cantly more patients in the 
bevacizumab group achieved a pathological complete response compared with those treated with chemotherapy alone: 
87 (22%, 95% CI 18–27) of 388 patients in the Bev+D-FEC group compared with 66 (17%, 13–21) of 393 patients in the 
D-FEC group (p=0·03). Grade 3 and 4 toxicities were reported at expected levels in both groups, although more patients 
had grade 4 neutropenia in the Bev+D-FEC group than in the D-FEC group (85 [22%] vs 68 [17%]).
Interpretation Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer signiﬁ cantly 
improved pathological complete response. However, whether the improvement in pathological complete response 
will lead to improved disease-free and overall survival outcomes is unknown and will be reported after longer follow-
up. Meta-analysis of available neoadjuvant trials is likely to be the only way to deﬁ ne subgroups of early breast cancer 
that would have clinically signiﬁ cant long-term beneﬁ t from bevacizumab treatment.
Funding Cancer Research UK, Roche, Sanoﬁ -Aventis.
Copyright © Earl et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Survival rates from early breast cancer have improved 
substantially over the past 20 years. However, the 
incidence of breast cancer has increased and continues to 
represent a major health problem worldwide.1 Both the 
Early Breast Cancer Trialists Collaborative Group 
(EBCTCG) overview analyses,2,3 and individual trial data 
have shown beneﬁ t for adjuvant anthracycline4–6 and 
taxane-containing chemotherapy.7–9 Although considerable 
progress has been made in early breast cancer through 
large adjuvant randomised treatment trials, these 
advances have been relatively slow. Follow-up is prolonged 
in order to meet the prespeciﬁ ed event rate criteria for 
disease-free survival and overall survival analyses, as 
deﬁ ned in the statistical analysis plans.10 Neoadjuvant 
trials in breast cancer have become increasingly common 
over the past 10 years, and the primary endpoint of 
pathological complete response can be reported more 
rapidly than in their adjuvant counterparts.
Neo-tAnGo was our previous randomised phase 3 
neoadjuvant trial and looked at the addition of 
gemcitabine to an anthracycline-based chemotherapy 
followed by taxane sequential combination,11 and also the 
eﬃ  cacy of giving paclitaxel ﬁ rst in the treatment 
sequence. Although the addition of gemcitabine did not 
prove eﬀ ective, giving paclitaxel ﬁ rst in the treatment 
sequence resulted in greater proportions of patients 
achieving a pathological complete response. Therefore, 
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in the ARTemis trial reported here we used a taxane ﬁ rst 
in the treatment sequence. At the time of development of 
the ARTemis trial in 2008, there was considerable interest 
in the role of bevacizumab in breast cancer because 
phase 3 trials had reported beneﬁ t in the metastatic 
setting.12,13 Other neoadjuvant breast cancer trials testing 
the eﬃ  cacy of bevacizumab (NSABP B-40 and 
GeparQuinto) had been announced. We developed the 
ARTemis randomised trial to test the hypothesis that the 
combination of bevacizumab with neoadjuvant 
anthracycline and taxane-based chemotherapy might 
improve the proportion of patients achieving a 
pathological complete response in breast cancer with 
acceptable toxicity. This study presents the results of the 
primary endpoint analysis.
Methods
Study design and participants
The ARTemis phase 3 randomised trial aimed to assess 
the beneﬁ t of the addition of neoadjuvant bevacizumab to 
chemotherapy in terms of short-term and long-term 
outcomes in women presenting with early breast cancer. 
We enrolled women aged 18 years or older with a 
histological diagnosis of early invasive breast cancer, and 
a radiological tumour size of more than 20 mm with or 
without axillary involvement. Patients were enrolled at 
66 National Cancer Research Network sites in the UK. 
Patients with inﬂ ammatory cancer, T4 tumours with 
direct extension to the chest wall or skin, and ipsilateral 
supraclavicular lymph node involvement were eligible 
with any size of primary tumour. We regarded hormone 
oestrogen receptor (ER) status as negative when Allred 
score was 0–2/8; ER weakly positive was 3–5/8; and ER 
strongly positive was 6–8/8. These ER categories were 
based on those already used by our group in the tAnGo 
trial14 and subsequently conﬁ rmed by Petit and colleagues15 
to be predictive of neoadjuvant chemotherapy response 
(pathological complete response) in ER-positive tumours. 
All patients were HER2 negative, deﬁ ned as 
immunohistochemistry of 0/1+, or if 2+, ﬂ uorescence in-
situ hybridisation showed no evidence of ampliﬁ cation of 
the HER2 gene. Other eligibility criteria were adequate 
cardiac function (left ventricular ejection fraction within 
the normal institutional range, as assessed by multiple-
gated acquisition scan or echocardiogram), adequate 
bone marrow, hepatic, and renal function, and appropriate 
Eastern Cooperative Oncology Group (ECOG) 
performance status (0–2). In view of potential side-eﬀ ects 
from bevacizumab, patients had to have no previous 
diagnosis of ischaemic heart disease, cerebrovascular 
disease, peripheral vascular disease, arterial or venous 
thromboembolic disease, cardiac failure, gastroduodenal 
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Research in context 
Evidence before this study
When the ARTemis trial was developed, survival from early 
breast cancer had improved over the preceding 20 years, in part 
through large randomised adjuvant treatment trials. Individual 
trials and the Early Breast Cancer Trialists Collaborative Group 
overviews had shown beneﬁ t for taxane and anthracycline 
chemotherapy, but intensiﬁ cation had failed to yield further 
rapid progress. Neoadjuvant trials in breast cancer have been 
increasingly pursued with the early primary endpoint of 
pathological complete response as a surrogate for activity and 
improvement in long-term outcomes. In 2008 there was great 
interest in the role of the anti-angiogenic monoclonal antibody 
bevacizumab because phase 3 trials of bevacizumab had 
reported beneﬁ t in the metastatic setting. Other neoadjuvant 
trials of bevacizumab in HER2-negative breast cancer were in 
progress or development including GeparQuinto, CALGB 40603, 
and NSABP B-40. We developed the ARTemis UK multicentre 
trial to test the hypothesis that the combination of bevacizumab 
with neoadjuvant taxane and anthracycline containing 
chemotherapy might improve the proportion of patients 
achieving a pathological complete response in HER2-negative 
breast cancer, with acceptable toxicity.  The ARTemis trial also 
collected tumour and blood from participants for future 
translational studies seeking molecular characteristics predicting 
beneﬁ t from bevacizumab, a key to optimising cost-
eﬀ ectiveness in future. 
Added value of this study
This report presents the primary endpoint of pathological 
complete response in ARTemis, showing a signiﬁ cant 
improvement in the proportion of patients achieving a 
pathological complete response with the addition of 
bevacizumab to neoadjuvant chemotherapy. Pathological 
complete response in oestrogen receptor (ER) strongly positive 
patients was achieved in fewer patients and did not appear to 
improve with bevacizumab, compared with ER negative and ER 
weakly positive patients.
Implications of all the available evidence
Our results extend those reported in GeparQuinto and CALGB 
40603, but also oﬀ er an explanatory hypothesis for the otherwise 
apparently divergent results of NSABP B-40, in which ER positive 
patients appeared to beneﬁ t most. We postulate that known 
variations between the trials in ER status deﬁ nition might have 
resulted in varying distribution of ER weakly positive patients 
across the dichotomised ER positive and negative categories, thus 
explaining the apparently divergent results. We also hypothesise 
that molecular characteristics of individual tumours, similar to 
those recently observed in ovarian cancer trials of bevacizumab, 
might correlate with ER status and underlie the variations in 
individual patient beneﬁ t observed.  Meta-analysis of ARTemis, 
GeparQuinto, CALGB 40603, and NSABP B-40 with analysis of 
their linked translational collections could test these hypotheses 
with suﬃ  cient statistical power in the future.
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ulcer, symptomatic diverticulitis, or inﬂ ammatory bowel 
disease. Additionally, no uncon trolled hypertension, 
deﬁ ned by a systolic pressure greater than 150 mm Hg or 
diastolic pressure greater than 90 mm Hg, with or 
without antihypertensive medication was allowed. 
Patients with initial increases in blood pressure were 
eligible if initiation or adjustment of antihypertensive 
medication lowered pressure to meet entry criteria.
No previous exposure to chemotherapy, radiotherapy, 
or endocrine therapy as treatment for breast cancer was 
allowed. Full eligibility criteria can be found in the trial 
protocol.
ARTemis was an investigator designed and led trial, 
granted a Clinical Trials Authorisation (CTA) from the 
Medicines and Healthcare products Regulatory Agency 
(MHRA) on Feb 25, 2009, approved by the Multi-Centre 
Research Ethics Committee nationally on March 26, 
2009, and subsequently by the local research ethics 
committees at all participating centres. All patients 
provided written informed consent.
Randomisation and masking
We randomly assigned participants (1:1) to two 
chemotherapy regimens using a central computerised 
minimisation procedure. Treatment allocations were made 
by telephone to the Warwick Clinical Trials Unit, where a 
central computerised minimisation procedure was used to 
generate the patients’ random allocation. Stratiﬁ cation by 
minimisation was done by age (≤50 years vs >50 years), ER 
status (negative vs weakly positive vs strongly positive), 
total tumour size (≤5 cm vs >5 cm), clinical involvement of 
axillary lymph nodes (yes vs no), and disease type 
(inﬂ ammatory or locally advanced or both vs neither). 
Randomisation was recommended within 4 weeks of the 
initial core biopsy and chemotherapy to start within 1 week 
of randomisation. The trial was open label.
Procedures
Chemotherapy regimens used were docetaxel 100 mg/m² 
once every 21 days for three cycles, followed by 
ﬂ uorouracil 500 mg/m², epirubicin 100 mg/m², with 
cyclophosphamide 500 mg/m² once every 21 days for 
three cycles (D-FEC). Bevacizumab 15 mg/kg (Genentech, 
South San Francisco and Vacaville, CA, USA) was given 
every 3 weeks with the ﬁ rst four cycles of chemotherapy 
in the experimental group (Bev+D-FEC).
We assessed adverse events for each chemotherapy 
cycle by grade according to Common Terminology 
Criteria for Adverse Events (CTCAE) version 3. We also 
recorded use of growth factor support (either granulocyte 
colony stimulating factor [GCSF] or pegylated [PEG] 
GCSF). The maximum permitted dose delay or 
interruption was 4 weeks to allow recovery from severe 
toxicity or for unscheduled procedures (eg, emergency 
surgery). If neutropenic fever or sepsis occurred after a 
cycle of chemotherapy, the next cycle was delayed until 
the absolute neutrophil count was at least 1·0 × 10⁹ cells 
per L. After a delay, either dose reduction of all drugs to 
80%, or GCSF support with 100% dose were allowed, and 
all remaining cycles of the same three-cycle block were 
given at those doses. For persistent thrombocytopenia, 
the next cycle was delayed until platelets had recovered to 
at least 100 × 10⁹ cells per L and chemotherapy doses were 
reduced to 80%, maintaining this dose reduction for 
subsequent cycles. Cycles from the next block of 
treatment were commenced at full protocol dose, and 
permitted delays and reductions were made as necessary. 
Primary prophylaxis with GCSF was allowed with 
docetaxel with or without bevacizumab, but not with FEC 
with or without bevacizumab. However, once started, 
prophylactic GCSF was usually continued into the 
second phase of chemotherapy at the discretion of the 
responsible physician.
If grade 2 neuropathy occurred during treatment with 
docetaxel, remaining doses were reduced to 75 mg/m². If 
grade 3 neuropathy occurred, docetaxel was stopped. If 
fewer than three cycles of docetaxel had been given, 
additional FEC cycles were allowed up to a maximum of 
six cycles in total, at the discretion of the treating 
consultant.
Cardiac toxicity was checked by left ventricular ejection 
fraction before treatment started and after four cycles of 
chemotherapy with or without bevacizumab. If congestive 
cardiac failure developed, patients were investigated and 
Figure 1: Trial proﬁ le
D-FEC=docetaxel 100 mg/m² once every 21 days, followed by ﬂ uorouracil 500 mg/m², epirubicin 100 mg/m², and 
cyclophosphamide 500 mg/m² once every 21 days. Bev+D-FEC=bevacizumab 15 mg/kg given every 3 weeks with 
the ﬁ rst four cycles of chemotherapy (D-FEC).
401 assigned to D-FEC
393 included in the primary 
 endpoint analysis
1 did not undergo surgery
 1 protocol violator refused surgery
1 did not have lymph node 
 examination after chemotherapy
6 withdrew consent for further 
 follow-up before surgery
6 were  ineligible
 4 with tumours 20 mm or less
 1 with a second breast tumour
    that was HER2-positive
 1 with liver metastases
8 had baseline blood pressure 
 measurements outside of the 
 protocol stated limits 
399 assigned to Bev+D-FEC
388 included in the primary 
 endpoint analysis
4 did not undergo surgery
    3 withdrew from the trial due to 
     early disease progression or 
     inadequate response to 
     chemotherapy
 1 had inflammatory disease after 
     neoadjuvant chemotherapy
7 withdrew consent for further 
 follow-up before surgery
1 ineligible because of bone 
 metastases
6 had baseline blood pressure 
 measurements outside of the 
 protocol stated limits
800 participants randomly assigned
For the trial protocol see www.
warwick.ac.uk/go/artemis
Articles
www.thelancet.com/oncology   Vol 16   June 2015 659
treated as appropriate, bevacizumab and epirubicin were 
discontinued, and other chemotherapy was given at the 
discretion of the treating clinician.
In the event of an allergic reaction to docetaxel, the 
infusion was stopped if mild symptoms of skin rash, 
ﬂ ushing, and localised pruritus occurred. Intravenous 
steroids and antihistamines were given and immediate 
slow rechallenge of chemotherapy was used on recovery. 
Docetaxel infusion was stopped if moderate symptoms of 
generalised pruritus or rash, mild dyspnoea, or mild 
hypotension occurred, and intravenous steroids and 
antihistamines were given. Steroids were then advised 
for 48 h before cautious docetaxel rechallenge. If severe 
allergic symptoms occurred, including bronchospasm, 
generalised urticaria, angio-oedema, hypotension 
(systolic blood pressure <100 mm Hg), or life-threatening 
anaphylaxis, docetaxel infusion was stopped and 
treatment was given with intramuscular epinephrine 
(1 mL, 1:1000), intravenous steroids, and intravenous 
antihistamines; rechallenge was contraindicated.
Surgery (breast and axillary), radiotherapy, and adjuvant 
endocrine treatment were done according to local 
protocols. Clinical surveillance will continue for 5 years 
at the clinical centres, and after 5 years with the Oﬃ  ce for 
National Statistics. Patients will continue to receive 
follow-up through the National Cancer Intelligence 
Network (NCIN) with monitoring of disease-free survival 
and overall survival.
The reporting of pathological complete response and 
minimal residual disease was by an independent, central, 
two-reader masked review of all anonymised local 
surgical histopathology reports undertaken by the co-
chief investigators (HME and LHa). When designing the 
trial, the primary endpoint pathological complete 
response was based on local report review and this is 
consistent with the study protocol. This manuscript 
adheres to our protocol and provides a measure 
comparable to other recent and similar trials 
(GeparQuinto, NSABP B-40, and CALGB 40603). When 
agreement was not reached, further review by the two 
study histopathologists (JT and EP) was done. In each 
case, a consensus on pathological complete response, 
and pathological complete response or minimal residual 
disease in the breast alone was agreed. Additionally, a 
detailed anonymised and masked central pathological 
review of all biopsies and surgical haematoxylin and 
eosin slides for pathological complete response is in 
progress. A quality assurance comparison (using a κ 
statistic) has been done in cases reviewed to date, 
between central pathological review of the haematoxylin 
and eosin slides (all cases done by JT) and the local 
histopathology reports for the primary endpoint of 
pathological complete response.
Outcomes
Our primary endpoint was pathological complete 
response, deﬁ ned as absence of invasive breast cancer in 
the breast and axillary lymph nodes, after neoadjuvant 
chemotherapy. Residual non-invasive ductal carcinoma 
in situ was allowed. Secondary endpoints included 
pathological complete response or minimal residual 
disease in the breast alone, which was deﬁ ned as 10% or 
D-FEC group 
(n=401)
Bev+D-FEC 
group (n=399)
Age*
≤50 years old 272 (68%) 271 (68%)
>50 years old 129 (32%) 128 (32%)
ER status*
Negative 126 (31%) 122 (31%)
Weakly positive 38 (10%) 37 (9%)
Strongly positive 237 (59%) 240 (60%)
Tumour size*
≤50 mm 318 (79%) 317 (79%)
>50 mm 83 (21%) 82 (21%)
Clinical involvement of axillary nodes*
No 193 (48%) 190 (48%)
Yes 208 (52%) 209 (52%)
Inﬂ ammatory or locally advanced disease or both*
No 325 (81%) 326 (82%)
Yes 76 (19%) 73 (18%)
Tumour type†‡
Ductal or no special type 317 (79%) 346 (87%)
Lobular 55 (14%) 42 (11%)
Tubular or cribriform 3 (<1%) 3 (<1%)
Mucinous 1 (<1%) 3 (<1%)
Medullary 1 (<1%) 1 (<1%)
Other 17 (4%) 5 (1%)
Not known 22 (5%) 15 (4%)
Tumour grade†
1, well diﬀ erentiated 7 (2%) 12 (3%)
2, moderately diﬀ erentiated 148 (37%) 130 (32%)
3, poorly diﬀ erentiated 203 (50%) 211 (53%)
Not known 43 (11%) 46 (12%)
Clinical characteristics†‡
Nipple retraction 32 (8%) 32 (8%)
Skin inﬁ ltration 15 (4%) 13 (3%)
Peau d’orange 23 (6%) 14 (4%)
Redness 14 (3%) 17 (4%)
Oedema 28 (7%) 31 (8%)
Other 95 (24%) 103 (26%)
None of the above 194 (48%) 192 (48%)
Not known 50 (12%) 52 (13%)
Ductal carcinoma in situ associated with tumour†
No 222 (55%) 221 (55%)
Yes 96 (24%) 100 (25%)
Not known 83 (21%) 78 (20%)
Data are n (%). *Stratiﬁ cation variables. †Each measurable breast tumour’s longest single diameter is summed within 
each breast for each patient, and labelled as tumour bulk; for each patient’s breast with maximum tumour bulk, 
tumour characteristics are presented. ‡Multiple types of tumour and characteristics can be recorded.
Table 1: Patient characteristics
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less of original tumour burden remaining at surgery, and 
has previously been reported as a potentially useful 
secondary endpoint in neoadjuvant studies.16
Other protocol-deﬁ ned secondary endpoints—that are 
not reported here—include disease-free survival and 
overall survival. These will be analysed in early 2016 
when it is anticipated that median follow-up will be at 
least 36 months or 120 disease-free survival events will 
have occurred.
Statistical analysis
The power calculations assume a 70 to 30 split in the trial 
sample between ER-positive and ER-negative tumours, 
respectively. The proportion of patients achieving a 
pathological complete response with the standard 
treatment (D-FEC) was estimated as about 10% for ER-
positive tumours and 25% for ER-negative tumours. On 
this basis, a trial randomly assigning 400 patients into 
each of the two treatment groups would allow an absolute 
diﬀ erence in the proportion of patients achieving a 
pathological complete response in excess of 10% to be 
detected at the 5% (two-sided) level of signiﬁ cance with 
an 85% power. A 10% diﬀ erence in the proportion of 
patients who achieve a pathological complete response is 
the most widely accepted in neoadjuvant chemotherapy 
trials and was used in this group’s previously reported 
Neo-tAnGo trial.11
The proportion of patients achieving pathological 
complete response was calculated for all patients known 
to have had surgery. The χ² test with continuity 
corrections was used to compare treatment groups. 
Multivariate logistic regression provided p values for the 
treatment eﬀ ect after adjustment for stratiﬁ cation factors.
As a secondary analysis, the proportion of patients 
achieving pathological complete response in the breast 
alone was assessed along with those achieving 
pathological complete response or minimal residual 
disease, and comparisons across treatment groups were 
made using multivariate logistic regression with 
adjustment for prognostic factors.
The sample size of our study is too small to permit 
multiple subgroup analyses, and so we chose not to do 
tests for statistical signiﬁ cance in each ER subgroup 
separately.
The methods for dose intensity calculations have been 
described previously.17 Chemotherapy course delivered 
dose intensities were compared across treatment groups 
using Wilcoxon rank-sum tests and Fisher’s exact tests.
Common Toxicity Criteria (CTC) grades were recorded 
for each chemotherapy cycle and growth factor support 
(usually GCSF) was also recorded. The reports of grade 3 
and 4 toxicities were examined in detail.
Statistical analysis was done on an intention-to-treat 
basis and therefore all patients who were ineligible, or 
whose treatment violated the trial protocol, were analysed 
within their randomised treatment groups. All reported 
p values are two-sided. Analysis was undertaken by 
Warwick Clinical Trials Unit, using SAS statistical 
D-FEC group Bev+D-FEC group p value*
n/N % (95% CI) n/N % (95% CI)
pCR in all breast tumours and absence of disease in all removed axillary 
lymph nodes (ypT0/Tis ypN0)†
66/393 17% (13–21) 87/388 22% (18–27) 0·03
ER negative (Allred 0–2) (n=241) 38/122 31% (23–40) 54/119 45% (36–55)
ER weakly positive (Allred 3–5) (n=74) 11/37 30% (16–47) 19/37 51% (34–68)
ER strongly positive (Allred 6–8) (n=466) 17/234 7% (4–11) 14/232 6% (3–10)
Grade 1/2‡ (n=293) 13/154 8% (5–14) 8/139 6% (3–11)
Grade 3 (n=403) 45/198 23% (17–29) 73/205 36% (29–43)
pCR in all breast tumours (ypT0/Tis) 76/394 19% (16–24) 99/388 26% (21–30) 0·02
ER negative (Allred 0–2) (n=241) 41/122 34% (25–43) 58/119 49% (39–58)
ER weakly positive (Allred 3–5) (n=75) 15/38 39% (24–57) 22/37 59% (42–75)
ER strongly positive (Allred 6–8) (n=466) 20/234 9% (5–13) 19/232 8% (5–12)
Grade 1/2‡ (n=293) 14/154 9% (5–15) 13/139 9% (5–15)
Grade 3 (n=404) 51/199 26% (20–32) 79/205 39% (32–46)
pCR or MRD in all breast tumours 114/394 29% (25–34) 138/388 36% (31–41) 0·03
ER negative (Allred 0–2) (n=241) 54/122 44% (35–54) 69/119 58% (49–67)
ER weakly positive (Allred 3–5) (n=75) 19/38 50% (33–67) 26/37 70% (53–84)
ER strongly positive (Allred 6–8) (n=466) 41/234 18% (13–23) 43/232 19% (14–24)
Grade 1/2‡ (n=293) 25/154 16% (11–23) 22/139 16% (10–23)
Grade 3 (n=404) 76/199 38% (31–45) 103/205 50% (43–57)
pCR=pathological complete response. MRD=minimal residual disease. *Adjusted for the ﬁ ve stratiﬁ cation variables (age [≤50 years, >50 years], ER status [negative, weakly 
positive, strongly positive], tumour size [≤50 mm, >50 mm], clinical involvement of axillary nodes [no, yes], and inﬂammatory or locally advanced disease [no, yes]). †Primary 
endpoint for the ARTemis trial. ‡Tumour grade of each patient’s largest breast tumour at baseline.
Table 2: Pathological complete response and minimal residual disease in D-FEC and Bev+D-FEC groups
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software (version 9.3). ARTemis is registered with 
EudraCT (2008-002322-11), ISRCTN (68502941), and 
ClinicalTrials.gov (NCT01093235).
Role of the funding source
The funders of the study (Cancer Research UK, Roche, 
and Sanoﬁ -Aventis) had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. HME, LHi, and LHa had full access to all of the 
data and had ﬁ nal responsibility for the decision to submit 
for publication with the agreement of all the authors and 
the data monitoring and safety committee.
Results
800 patients were recruited at 66 UK centres (between 
May 7, 2009, and Jan 9, 2013) and randomly assigned to 
either D-FEC (401 patients) or Bev+D-FEC regimens 
(399 patients; ﬁ gure 1). Patient and tumour characteristics 
were balanced across treatment groups (table 1). We 
subsequently identiﬁ ed seven patients as ineligible; six 
in the D-FEC group (four with tumours 20 mm or less, 
one with a second breast tumour that was HER2-positive, 
and one with liver metastases); and one in the Bev+D-FEC 
group (with bone metastases). Additionally, 14 patients 
(eight in the D-FEC group and six in the Bev+D-FEC 
group) had baseline blood pressure measurements 
outside of the protocol stated limits. All patients were 
included in analyses on an intention-to-treat basis. 
782 patients had post-chemotherapy pathology reports 
from surgery available for review, 781 of which could be 
used for assessment of the primary endpoint of absence 
of invasive breast cancer in the breast and axillary lymph 
nodes. 153 (20%) of all 781 patients achieved a pathological 
complete response: 66 (17%, 95% CI 13–21) in the D-FEC 
group and 87 (22%, 18–27) in the Bev+D-FEC group 
(diﬀ erence 6%, 0·1–11·2; p=0·03 after adjustment for 
stratiﬁ cation factors, p=0·06 for the unadjusted analysis; 
table 2 and ﬁ gure 2). The proportion of patients overall 
who achieved a pathological complete response diﬀ ered 
signiﬁ cantly across both ER status (ER negative 38% 
[95% CI 32–45], weakly positive 41% [29–53], strongly 
positive 7% [5–9]; p<0·0001), and tumour grade 
(grade 1/2 7% [4–11], grade 3 29% [25–34]; p<0·0001). ER 
negative, ER weakly positive, and grade 3 patients 
appeared to beneﬁ t from the addition of bevacizumab 
whereas ER strongly positive and grade 1/2 patients did 
not appear to beneﬁ t from the addition of bevacizumab 
(table 2). An analysis of beneﬁ t for bevacizumab for each 
level of Allred score (ER status), conﬁ rmed that our 
categories of ER weakly positive (Allred 3–5/8) and ER 
strongly positive (Allred 6–8/8) were the correct cut 
points both for pathological complete response rate and 
beneﬁ t for bevacizumab (appendix). Complete central 
pathology specimen review for the trial is in progress and 
will be reported later. Preliminary results show very good 
agreement between central pathology review and local 
pathology report review for pathological complete 
response in the breast and axilla (agreement in 95% of 
cases, κ 0·83 [95% CI 0·76–0·90]).
The proportion of patients achieving a pathological 
complete response in the breast alone was signiﬁ cantly 
higher in the Bev+D-FEC group than in the D-FEC group 
(diﬀ erence 6% [95% CI 0·1–12·1]; p=0·02 after 
adjustment for stratiﬁ cation factors; table 2). Pathological 
complete response diﬀ ered signiﬁ cantly across both ER 
status (negative 41% [95% CI 35–48], weakly positive 49% 
[38–61], strongly positive 8% [6–11]; p<0·0001) and 
tumour grade (grade 1/2 9% [6–13], grade 3 32% [28–37]; 
p<0·0001). Similarly, the proportion of patients who 
obtained a pathological complete response or minimal 
residual disease was signiﬁ cantly better in the Bev+D-
FEC group than in the D-FEC group (diﬀ erence 7% 
[95% CI 0·1–13·2]; p=0·03 after adjustment for 
stratiﬁ cation factors; table 2). The proportion of patients 
who obtained a pathological complete response or 
minimal residual disease  diﬀ ered signiﬁ cantly across 
both ER status (negative 51% [95% CI 45–58], weakly 
positive 60% [48–71], strongly positive 18% [15–22]; 
p<0·0001) and tumour grade (grade 1/2 16% [12–21], 
grade 3 44% [39–49]; p<0·0001). An exploratory analysis 
of inﬂ ammatory breast cancers was done and the results 
Figure 2: Eﬀ ect of bevacizumab on pathological complete response according to oestrogen receptor (ER) status 
Pathological complete response (n/N)
D-FEC
ER negative
ER weakly positive
ER strongly positive
Overall
 38/122 (31%)
 11/37 (30%)
 17/234 (7%)
 66/393 (17%)
Bev+D-FEC
54/119 (45%)
 19/37 (51%)
 14/232 (6%)
 87/388 (22%)
10 2 3 4
Favours D-FEC Favours Bev+D-FEC
OR (95% CI)
See Online for appendix
Number of 
patients
Allergic reaction to docetaxel; switched to FEC early 11
Wound complications or infection 10
Hypertension 9
Chemotherapy toxicity (withdrew from trial or switched to 
FEC)
6
Progression or no change—decision to switch to FEC or to 
surgery
5
Bleeding 5
Venothromboembolism 3
Cardiac symptoms 2
MRI head-meningioma; patient withdrew from trial 1
Allergic reaction to bevacizumab 1
Table 3: Reasons for 53 patients not having bevacizumab administered 
for four cycles
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showed no signiﬁ cant advantage for bevacizumab, 
although the sample sizes are too small to draw any 
conclusions (data not shown).
779 (97%) patients had full treatment details available 
(391 [98%] of 401 patients in the D-FEC group and 
388 [97%] of 399 in the Bev+D-FEC group). Four patients 
in the Bev+D-FEC group received no treatment cycles for 
the following reasons: diagnosis of colitis and patient 
proceeded to mastectomy with axillary surgery; patient 
chose to withdraw from trial before any treatment was 
given; allergic reaction and no chemotherapy given; 
diagnosis of metastatic disease during the trial screening 
phase.
695 (90%) of 775 patients (352 [90%] of 391 patients in 
the D-FEC group and 343 [89%] of 384 in the Bev+D-FEC 
group) who started treatment received six cycles of 
chemotherapy; the main reasons for receiving fewer 
cycles being patient withdrawal, allergic reaction to drugs, 
and chemotherapy toxicities. The median chemotherapy 
course delivered dose intensity for the 779 patients was 
97% (IQR 92–100). No diﬀ erences in chemotherapy 
course delivered dose intensity between the treatment 
groups were detected (D-FEC 98% [95% CI 92–100] vs 
Bev+D-FEC 97% [91–100]; p=0·24). 665 (85%) patients 
received a chemotherapy course delivered dose intensity 
of at least 85% (D-FEC 86% [95% CI 82–89] vs Bev+D-
FEC 85% [81–88]; p=0·58). 14 (4%) of 391 D-FEC patients 
switched to FEC early (one at cycle 1, four at cycle 2, and 
nine at cycle 3). Nine (2%) of 384 Bev+D-FEC patients 
switched to FEC early (two at cycle 2 and seven at cycle 3). 
The main reason for switching early was allergy to 
docetaxel (19 [83%] of 23 patients; 11 [79%] of 14 D-FEC 
patients, eight [89%] of nine Bev+D-DFEC patients).
331 (86%) of 384 Bev+D-FEC patients who started 
treatment received four cycles of bevacizumab. 53 patients 
stopped bevacizumab early because of allergic reaction to 
docetaxel (so switching to FEC early), wound complications, 
and hypertension (table 3). The median bevacizumab 
course delivered dose intensity for the 388 Bev+D-FEC 
patients was 99% (IQR 95–101). 85% (95% CI 81–88%) of 
Bev+D-FEC patients received a bevacizumab course 
delivered dose intensity of at least 85%.
The individual cycle dose intensities both for 
chemotherapy and bevacizumab did not show substantial 
attrition over time (appendix). There were also no 
substantial diﬀ erences between the docetaxel and the 
FEC blocks of chemotherapy (data not shown). Of the 
386 (9%) reports of chemotherapy dose reductions from 
4418 chemotherapy cycles, dose reductions were most 
commonly reported in cycles 2 and 3 and again in cycles 5 
and 6, in both treatment groups (table 4). A slight 
increase in reports of treatment delays was also noted in 
cycles 2, 5, and 6 across both treatment groups (table 4). 
Reports of modiﬁ cations to bevacizumab administration 
were infrequent throughout the four cycles (table 5).
GCSF was used in 2744 (62%) of 4418 cycles with 
slightly higher rates in the Bev+D-FEC group in all 
treatment cycles (appendix). GCSF was used in 626 (81%)
of 775 patients: 301 (77% [95% CI 73–81]) in the D-FEC 
group and 325 (85% [95% CI 81–88]) in the Bev+D-FEC 
group (p=0·009). No patients died during chemotherapy, 
or within 4 months of chemotherapy completion. No 
patient deaths after this time were attributed to their 
randomly assigned treatment. Full treatment details 
were available for 4418 cycles delivered to 775 patients 
(2234 cycles in 391 D-FEC patients and 2184 cycles in 
384 Bev+D-FEC patients). Reported severe toxicities by 
patient showed no unexpected ﬁ ndings (table 6). More 
patients receiving bevacizumab with D-FEC had grade 3 
infections than those receiving D-FEC alone (68 [18%] vs 
40 [10%]). Allergies were reported separately: 43 (5%) of 
800 patients (26 D-FEC patients, 17 Bev+D-FEC patients)
had grade 3 and 4 allergic reactions attributable to 
docetaxel and only one patient had grade 3 allergy 
attributable to bevacizumab. 153 (20%) patients had 
grade 4 neutropenia, 13 (2%) had grade 4 infection, and 
six (<1%) had grade 4 fatigue (table 6). More patients in 
the Bev+D-FEC group had grade 4 neutropenia than 
those in the D-FEC group (85 [22%] vs 68 [17%]). No 
adverse drug reactions were both serious and unexpected. 
In total, 461 serious adverse events were reported, 196 by 
D-FEC patients and 265 by Bev+D-FEC patients. Both 
regimens appear tolerable and deliverable.
Full surgery details were available for 764 (98%) of 
781 patients (378 D-FEC patients, 386 Bev+D-FEC 
patients) analysed for pathological complete response by 
local report review. The Bev+D-FEC group did not have 
D-FEC group Bev+D-FEC group
Number of 
dose 
reductions
Number of 
treatment 
delays
Number of 
dose 
reductions
Number of 
treatment 
delays
Cycle 1 6 (2%) 18 (5%) 4 (1%) 11 (3%)
Cycle 2 48 (12%) 38 (10%) 60 (16%) 42 (11%)
Cycle 3 60 (16%) 18 (5%) 65 (18%) 22 (6%)
Cycle 4 9 (2%) 21 (6%) 15 (4%) 18 (5%)
Cycle 5 26 (7%) 46 (13%) 36 (10%) 37 (10%)
Cycle 6 30 (9%) 38 (11%) 27 (8%) 21 (6%)
Data are n (%). 
Table 4: Chemotherapy modiﬁ cations in the 4418 cycles
Number not given as per 
protocol
Number of treatment 
delays
Cycle 1 6 (2%) 11 (3%)
Cycle 2 7 (2%) 31 (9%)
Cycle 3 3 (<1%) 17 (5%)
Cycle 4 2 (<1%) 14 (4%)
Data are n (%). 
Table 5: Bevacizumab modiﬁ cations in the 1426 cycles in the Bev+D-FEC 
group
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signiﬁ cantly lower proportions of patients having 
mastectomy compared with the D-FEC group (48% vs 
51%; p=0·47; appendix). However, overall, signiﬁ cantly 
fewer patients who achieved a pathological complete 
response had a mastectomy compared with those who 
did not achieve a pathological complete response  (42/146 
[29%] vs 335/618 [54%]; p<0·0001; appendix). Having a 
pathological complete response or minimal residual 
disease in the breast also signiﬁ cantly lowered the 
frequency of mastectomy compared with those patients 
who achieved neither (90/243 [37%] vs 287/522 [55%] 
p<0·0001; appendix).
Discussion
In the ARTemis study, the addition of short course 
bevacizumab to standard neoadjuvant anthracycline and 
taxane-based chemotherapy in HER2-negative, early 
breast cancer, was associated with a signiﬁ cant 
improvement in the proportion of patients achieving a 
pathological complete response. A greater proportion of 
ER-negative (Allred 0–2) and ER weakly positive (Allred 
3–5) patients achieved pathological complete response 
compared with the ER strongly positive (Allred 6–8) 
patients. Additionally, bevacizumab combined with 
chemotherapy appeared to provide more signiﬁ cant 
beneﬁ t to ER-negative and ER weakly positive patients 
than to other types. The beneﬁ t of bevacizumab for 
ER-negative and weakly positive patients is in marked 
contrast to the ER strongly positive group in which low 
proportions of patients achieved pathological complete 
response and there was also an apparent lack of beneﬁ t 
from bevacizumab. The ARTemis treatment protocol was 
deliverable for both chemotherapy and bevacizumab, 
and toxicity from chemotherapy was as expected for 
D-FEC, although there was an increase in grade 4 
neutropenia in patients given Bev+D-FEC, as reported 
previously.18 The observed diﬀ erences in pathological 
complete response were statistically signiﬁ cant in the 
group as a whole. However, the clinical signiﬁ cance of 
the addition of bevacizumab appears to be most 
compelling within the ER-negative subgroup.
Three other randomised studies have reported on the 
addition of bevacizumab to neoadjuvant chemotherapy 
in HER2-negative breast cancer19–22 (appendix). Patho-
logical complete response was the primary endpoint in 
all four studies, albeit with diﬀ ering deﬁ nitions. In 
GeparQuinto, pathological complete response was 
deﬁ ned as lack of invasive or in situ cancer in both breast 
and axilla (ypT0 ypN0). Using this stringent deﬁ nition, 
bevacizumab signiﬁ cantly increased the proportion of 
patients achieving pathological complete response in the 
bevacizumab-containing group compared with the 
chemotherapy alone group (18·4% vs 14·9%; p=0·04) in 
the overall study population.19 Bevacizumab signiﬁ cantly 
increased the proportion of patients achieving a 
pathological complete response in the 633 patients with 
triple-negative disease (27·9% increased  to 39·3%, 
p=0·003) but not in the 1262 patients with hormone-
receptor-positive tumours (7·7% increased to 7·8%, 
p=1·0). The GeparQuinto results are supported by those 
of CALGB 40603, which enrolled triple-negative patients 
only.20 In this smaller study, the addition of bevacizumab 
signiﬁ cantly increased the proportion of patients 
achieving a pathological complete response (deﬁ ned as 
absence of invasive disease in breast only [ypT0/Tis]) in 
the bevacizumab group compared with the chemotherapy 
alone group (59% vs 48%; p=0·009). The results of these 
two studies are very similar to our study, in which a 
greater proportion of patients treated with bevacizumab 
achieved a pathological complete response (deﬁ ned as 
no invasive disease in breast or axilla [ypT0/Tis ypN0]) 
than those treated with chemotherapy alone (22% vs 17% 
in the overall study population and 44% vs 32% in ER/
HER2-negative patients). Contrary to these three studies, 
in NSABP B-40, the addition of bevacizumab increased 
the proportion of patients achieving a pathological 
complete response (deﬁ ned as ypT0/Tis) in hormone-
receptor-positive breast cancers when compared with the 
chemotherapy alone group (23·2% vs 15·1%, p=0·007) 
but not in triple-negative patients (51·5% vs 
47·1%, p=0·34).21
Several points can be made if one is to try to reconcile 
the diﬀ erences in outcomes between these four studies. 
First, since the tests for interaction between hormone 
receptor status and treatment group were non-
signiﬁ cant in both NSABP B-40 and GeparQuinto, a 
statistical diﬀ erential eﬀ ect of bevacizumab according 
to hormone receptor has not yet been proven. Second, 
all four studies used diﬀ erent chemotherapy backbones 
and both NSABP B-40 and CALGB 40603 had factorial 
designs where modiﬁ cations of the chemotherapy 
regimens were tested in parallel with the addition of 
bevacizumab, rendering cross-trial comparisons even 
more diﬃ  cult. As an example, in CALGB 40603, the 
D-FEC group (n=391) Bev+D-FEC group (n=384)
Grade 1/2 Grade 3 Grade 4 Grade 1/2 Grade 3 Grade 4
Neutropenia 62 (16%) 78 (20%) 68 (17%) 51 (13%) 83 (22%) 85 (22%)
Infection 141 (36%) 40 (10%) 4 (1%) 129 (34%) 68 (18%) 9 (2%)
Fatigue 359 (92%) 28 (7%) 4 (1%) 351 (91%) 37 (10%) 2 (<1%)
Diarrhoea 203 (52%) 20 (5%) 0 208 (54%) 15 (4%) 1 (<1%)
Nausea 306 (78%) 17 (4%) ·· 294 (77%) 13 (3%) ··
Vomiting 129 (33%) 7 (2%) 0 145 (38%) 14 (4%) 0
Hypertension 36 (9%) 6 (2%) 0 50 (13%) 8 (2%) 0
Constipation 243 (62%) 5 (1%) 0 231 (60%) 5 (1%) 0
Peripheral neuropathy 199 (51%) 4 (1%) 0 201 (52%) 6 (2%) 0
Proteinuria 10 (3%) 0 0 53 (14%) 1 (<1%) 0
Alopecia 365 (93%) ·· ·· 352 (92%) ·· ··
Data are n (%). Alopecia does not have a Common Terminology Criteria for Adverse Events (CTCAE) grade of 3 or 4. 
Nausea does not have a CTCAE grade of 4.
Table 6: Adverse events
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proportion of patients who received both carboplatin 
and bevacizumab with standard chemotherapy and 
achieved a pathological complete response (deﬁ ned as 
ypT0/Tis ypN0) was numerically highest (60%), 
compared with patients who received either carboplatin 
and standard chemotherapy (49%), bevacizumab and 
standard chemotherapy (43%), or standard 
chemotherapy alone (39%).20 Third, in GeparQuinto, 
patients with no clinical response after the ﬁ rst 
anthracycline-based component of the study were 
removed from the study, potentially introducing bias 
that is diﬃ  cult to quantify.19 Fourth, whereas hormone-
receptor-positive patients were deﬁ ned as those showing 
more than 10% positive cells for either ER or 
progesterone receptor in GeparQuinto and CALGB 
40603, the NSABP B-40 trial used a 1% cutoﬀ . We used 
an Allred score greater than 2 to identify ER-positive 
patients, a deﬁ nition very close to that of NSABP B-40. 
In our trial, ER weakly positive patients (although a 
small stratiﬁ ed subgroup; n=75) showed similar 
chemotherapy response and beneﬁ t from bevacizumab 
to the ER-negative group. Therefore, it is possible that 
the increased proportion of patients who achieved a 
pathological complete response in ER-positive 
patients in NSABP B-40 is driven by patients with low 
ER scores who were excluded from GeparQuinto and 
CALGB 40603.
A point of convergence can be found if pathological 
complete response is deﬁ ned as we have in our study (ie, 
absence of invasive disease in breast and axilla but 
allowing residual ductal carcinoma in situ in the breast 
[ypT0/Tis ypN0]). This is reported as the primary 
outcome in our study and as a secondary endpoint in the 
other three studies. Using this deﬁ nition, pathological 
complete response is not signiﬁ cantly higher with the 
addition of bevacizumab in the overall study population 
in any of the three previously reported studies.19–21 
However, pathological complete response is still 
signiﬁ cantly improved in triple-negative patients in 
GeparQuinto23 and in hormone-receptor-positive patients 
in NSABP B-40. We believe that a meta-analysis of all 
four studies with uniform deﬁ nitions of hormone 
receptor and pathological complete response is needed to 
identify a subgroup of patients in whom bevacizumab 
increases pathological complete response. With that in 
mind, and acknowledging that the sample size of our 
study is too small for subgroup analyses, we chose not to 
do tests for statistical signiﬁ cance in each ER subgroup 
separately (table 2).
The use of pathological complete response as a trial 
endpoint is to some extent dependent on its role as a 
surrogate for meaningful clinical outcomes such as 
disease-free survival, distant relapse-free interval, breast 
cancer speciﬁ c survival, and overall survival. Some of 
these have very recently been reported for the 
GeparQuinto study24 and show no diﬀ erence for the 
addition of bevacizumab at 3 years for either disease-free 
survival (HR 1·03, 95% CI 0·84–1·25) or overall survival 
(0·97,  0·75–1·26). Results might be confounded because 
no bevacizumab was given after surgery and patients 
who were not responding on ultrasound assessment, at 
the midpoint of their neoadjuvant treatment, were 
oﬀ ered randomisation into a novel treatment group with 
everolimus. Another explanation is that since 
bevacizumab is a targeted anti-angiogenic agent, it is 
potentially less likely to eradicate micrometastatic disease 
in the bone marrow. We hypothesise that there is unlikely 
to be synergism between chemotherapy and bevacizumab 
in the bone marrow because this disease is not dependent 
on angiogenesis for its survival. Whereas an increased 
incidence of pathological complete response occurs in 
the well-developed primary tumour, which is angio-
genesis-dependent, there might be no such advantage in 
terms of increased eradication of eventually lethal distant 
micrometastatic bone marrow disease. An indication 
that this mechanism might be operating is provided by 
the observation that patients who achieved pathological 
complete response in the bevacizumab group in the 
GeparQuinto trial had double the risk of relapse of those 
in the chemotherapy-only group (HR 2·02, 95% CI 
0·965–4·22).24 Additionally, precisely because 
bevacizumab is an anti-angiogenic agent, once the 
treatment course is completed, there might be a rebound 
of tumour cell growth, as has been reported in advanced 
ovarian cancer after completion of bevacizumab therapy.25 
Similar mechanisms could explain the lack of beneﬁ t 
from adjuvant bevacizumab added to standard 
chemotherapy, reported in both the BEATRICE trial26 and 
the ECOG Study E5103.27
At the 2014 San Antonio Breast Cancer Symposium, 
the NSABP B-40 group presented disease-free survival, 
distant recurrence-free interval, and overall survival 
results28 with a median follow-up of 4·7 years. These 
results were surprisingly diﬀ erent from those of the 
recently published GeparQuinto, and showed beneﬁ t for 
bevacizumab given in the neoadjuvant setting followed 
by adjuvant treatment. For ER-positive patients the HRs 
for disease-free survival, distant recurrence-free interval, 
and overall survival were 0·73 (95% CI 0·53–1·00; 
p=0·05), 0·68 (0·47–0·97; p=0·03), and 0·63 (0·42–0·96; 
p=0·03), respectively. The inclusion of adjuvant 
bevacizumab in the NSABP B-40 study is the major 
diﬀ erence between these four neoadjuvant bevacizumab 
studies and might be an important factor in explaining 
the beneﬁ t of bevacizumab on longer term outcomes in 
this trial, although this was not conﬁ rmed in the adjuvant 
studies.26,27 Another explanation is that with a median 
follow-up of 4·7 years, it is too early to draw conclusions 
about overall survival and distant recurrence-free interval 
in the ER-positive group in this trial.10
The relation between the primary endpoint of patho-
logical complete response in therapeutic neoadjuvant 
trials and longer term outcomes is complex. Hatzis  and 
colleagues29 have explored this in depth, and  have 
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modelled data from neoadjuvant trials and made two 
conclusions. First, that in high-risk breast cancer the 
design of neoadjuvant trials could increase the numbers 
of patients to a level that would make a positive 
correlation between the primary endpoint (proportion of 
patients achieving pathological complete response) and 
longer term outcomes more likely. Second, that including 
lesser degrees of pathological response could improve 
the correlation between a (thereby newly deﬁ ned) 
primary endpoint of pathological response. Pathological 
complete response has been convincingly proven to be a 
strong positive predictive factor for improved event-free 
survival and overall survival in individual patients by the 
Collaborative Trials in Neoadjuvant Breast Cancer 
(CTNeoBC) Consortium.30 In their analysis, pathological 
complete response, deﬁ ned as ypT0/Tis ypN0, resulted 
in improved event-free survival (HR 0·48, 
95% CI 0·43–0·54) and overall survival (0·36, 0·31–0·42). 
This relation, however, breaks down at the trial level. In 
the CTNeoBC analysis of 12 trials and 11 955 patients, the 
coeﬃ  cient of determination (R²) was only 0·03 for event-
free survival and 0·24 for overall survival, meaning that 
only 3% and 24% of the variability in event-free survival 
and overall survival, respectively, between trial groups 
can be explained by diﬀ ering proportions of patients 
achieving a pathological complete response. These 
results have been corroborated in a further trial-level 
analysis of 29 trials and 14 641 patients that reported R² 
values of 0·08 and 0·09 for disease-free survival and 
overall survival, respectively.31 In light of this, the Food 
and Drug Administration accelerated licensing approval 
for new compounds doing well in neoadjuvant breast 
cancer studies in early breast cancer subtypes with high 
risk of recurrence32 should be treated with caution, and 
depending on the results from trials of newer targeted 
agents, might need modiﬁ cation in the future.
Are there potential independent tumour biomarkers of 
response to bevacizumab available? The recent report at 
the American Society for Clinical Oncology 2014 annual 
meeting of an expression signature for angiogenesis in 
ovarian cancer33 is an exciting development. This signature 
might prove to be a poor prognosis biomarker in epithelial 
ovarian cancer, and might be predictive for beneﬁ t from 
bevacizumab. Absence of this signature in epithelial 
ovarian cancer possibly denotes good prognosis disease 
and paradoxically detrimental eﬀ ect from the addition of 
bevacizumab to standard chemo therapy. These results 
need to be tested prospectively in other datasets. The 
translational ARTemis group plan to explore, using 
samples from the ARTemis trial biobank, whether the 
same angiogenic signature in breast cancer could provide 
a predictive biomarker of response to bevacizumab.
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